

DELIVERING **15 YEARS*** OF **CONTINUOUS** **DBS THERAPY.**

Extending the service life of Activa™ RC — just one part of our unrivaled commitment to DBS therapy.

* Activa™ RC devices eligible for the service life extension and the supplemental limited warranty are those devices sold in the US that have been successfully interrogated with the Medtronic Activa Clinician Programmer prior to reaching End of Service (EOS).

Medtronic
Further. Together

MISSION DRIVEN. PATIENT FOCUSED.

Patients with high energy requirements have benefitted from rechargeable technology from Medtronic DBS since 2009. Giving them more time between replacements. Now, we are taking this commitment even further by extending our Activa™ RC longevity from 9 to 15 years*.

* Activa™ RC devices eligible for the service life extension and the supplemental limited warranty are those devices sold in the US that have been successfully interrogated with the Medtronic Activa Clinician Programmer prior to reaching End of Service (EOS).

WHAT CAN **6 MORE YEARS** MEAN TO YOUR PATIENTS?



15 years* between stimulator replacements.



Extended 15 year* INS Warranty.



Peace of mind.

TOTAL DEVICE RELIABILITY AND A WARRANTY* TO MATCH.


Our battery is just the beginning.

Patients need a DBS device that delivers consistent therapy over the course of its lifespan. At Medtronic, we don't just test the battery—we test the entire device. So you can feel confident you're giving your patients a predictable recharge experience from a long lasting device.

PROVEN BATTERY PERFORMANCE.

In 2009, when we launched the first rechargeable technology in the DBS market, we felt confident that our devices would provide predictable performance for up to nine years. This confidence was based largely on accelerated lab-testing. Today, as part of our commitment to the Medtronic mission to DBS therapy, we have invested in post-market analysis and continuous device testing to validate our predictive models, and confidently **extend device service life from 9 to 15 years***.

Even under a variety of use conditions, The Activa™ RC battery capacity fade is limited over time so as not to negatively impact the patient recharge experience.



Activa™ RC predicted recharge intervals for movement disorder patients. Percentiles correspond to patient groups that need different energy levels. Recharge interval corresponds to the maximum time allowed between recharge events. In practice more frequent recharge behavior might be seen.



The Activa™ RC
can maintain
a predictable
recharge
experience
over 15 years*.

Brief Statement: Medtronic DBS Therapy for Parkinson's Disease and Tremor

Medtronic DBS Therapy for Parkinson's Disease and Tremor: Product labeling must be reviewed prior to use for detailed disclosure of risks.

Indications:

Medtronic DBS Therapy for Parkinson's Disease: Bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic DBS Therapy for Parkinson's Disease is indicated for adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson's disease of at least 4 years' duration that are not adequately controlled with medication, including motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.

Medtronic DBS Therapy for Tremor: Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) using Medtronic DBS Therapy for Tremor is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.

Contraindications: Medtronic DBS Therapy is contraindicated for patients who are unable to properly operate the neurostimulator and patients for whom test stimulation is unsuccessful. The following procedures are contraindicated for patients with DBS systems: diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy), which can cause neurostimulation system or tissue damage and can result in severe injury or death; Transcranial Magnetic Stimulation (TMS); and certain MRI procedures using a full body transmit radio-frequency (RF) coil, a receive-only head coil, or a head transmit coil that extends over the chest area if the patient has an implanted Soletra Model 7426 Neurostimulator, Kinetra Model 7428 Neurostimulator, Activa SC Model 37602 Neurostimulator, or Model 64001 or 64002 pocket adaptor.

Warnings and Precautions: There is a potential risk of brain tissue damage using stimulation parameter settings of high amplitudes and wide pulse widths and a potential risk to drive tremor using low frequency settings. Extreme care should be used with lead implantation in patients with an increased risk of intracranial hemorrhage. Sources of electromagnetic interference (EMI) may cause device damage or patient injury. Theft detectors and security screening devices may cause stimulation to switch ON or OFF and may cause some patients to experience a momentary increase in perceived stimulation. The DBS System may be affected by or adversely affect medical equipment such as cardiac pacemakers or therapies, cardioverter/ defibrillators, external defibrillators, ultrasonic equipment, electrocautery, or radiation therapy. MRI conditions that may cause excessive heating at the lead electrodes which can result in serious injury, including coma, paralysis, or death, or that may cause device damage, include: neurostimulator implant location other than pectoral and abdominal regions; unapproved MRI parameters; partial system explants ("abandoned systems"); misidentification of neurostimulator model numbers; and broken conductor wires (in the lead, extension or pocket adaptor). The safety of electroconvulsive therapy (ECT) in patients receiving DBS Therapy has not been established. Tunneling the extension too superficially or too deeply may result in nerve or vascular injury, or tunneling through unintended anatomy. The lead-extension connector should not be placed in the soft tissues of the neck due to an increased incidence of lead fracture. Abrupt cessation of stimulation should be avoided as it may cause a return of disease symptoms, in some cases with intensity greater than was experienced prior to system implant ("rebound" effect). Patients using a rechargeable neurostimulator should check for skin irritation or redness near the neurostimulator during or after recharging, and contact their physician if symptoms persist. Loss of coordination in activities such as swimming may occur. Depression, suicidal ideations and suicide have been reported in patients receiving Medtronic DBS Therapy for Movement Disorders, although no direct cause-and-effect relationship has been established.

Adverse Events: Adverse events related to the therapy, device, or procedure can include intracranial hemorrhage, cerebral infarction, CSF leak, pneumocephalus, seizures, surgical site complications (including pain, infection, dehiscence, erosion, seroma, and hematoma), meningitis, encephalitis, brain abscess, cerebral edema, aseptic cyst formation, device complications (including lead fracture and device migration) that may require revision or explant, extension fibrosis (tightening or bowstringing), new or exacerbation of neurological symptoms (including vision disorders, speech and swallowing disorders, motor coordination and balance disorders, sensory disturbances, cognitive impairment, and sleep disorders), psychiatric and behavioral disorders (including psychosis and abnormal thinking), cough, shocking or jolting sensation, ineffective therapy and weight gain or loss.

Safety and effectiveness has not been established for patients with neurological disease other than idiopathic Parkinson's disease or Essential Tremor, previous surgical ablation procedures, dementia, coagulopathies, or moderate to severe depression, patients who are pregnant, or patients under 18 years. Safety and effectiveness of Medtronic DBS Therapy for Tremor has not been established for bilateral stimulation or for patients over 80 years of age.

USA Rx only Rev 11/17

Knowing that I can postpone surgery for so long is better for me and my family.

-Amybel, Patient receiving DBS Therapy with Activa™ RC



Actual patient not pictured

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Tel: (763) 514-4000
Fax: (763) 514-4879
Toll-free: 1 (800) 328-2518
24-hour technical support for
physicians and medical professionals

UC201809586 EN © Medtronic, Inc.
2018, Minneapolis, MN. All Rights Reserved.
Printed in USA. 05/2018

medtronic.com